Genitourinary Radiology: Page 47

C-11 choline PET/MRI helps restage prostate cancer patients
By Wayne Forrest
A preliminary study by German researchers suggests that carbon-11 (C-11) choline PET/MRI may provide an alternative imaging modality to PET/CT for restaging of prostate cancer by offering equal, if not better, diagnostic performance and less radiation exposure.
December 25, 2012
Study finds CT radiation risk may be overestimated
By Eric Barnes
The risks from testicular cancer far outweigh the radiation risk from CT exams used to diagnose and monitor it, concludes a study published today in Radiology. While the study was limited to testicular cancer, it illustrates a common mistake being made in estimating the risk of radiation from medical imaging exams.
December 17, 2012
Is proton therapy worth the cost for prostate cancer?
By Cynthia E. Keen
Is the use of proton therapy for localized prostate cancer worth the cost? A national study of 30,000 men suggests it might not be. Findings were published online December 14 in the Journal of the National Cancer Institute.
December 16, 2012
Elekta gets FDA OK for monitoring software
By AuntMinnie.com staff writers
Radiation oncology firm Elekta has received U.S. Food and Drug Administration 510(k) clearance for its Clarity 4D monitoring software, which monitors motion in the prostate and surrounding tissues and organs during radiation therapy for prostate cancer.
December 16, 2012
Fused MRI, ultrasound aids prostate cancer detection
By AuntMinnie.com staff writers
Fusing MR and real-time ultrasound images to sample tumor spots can help detect and diagnose prostate cancer and, as a result, reduce the number of prostate biopsies, according to a study published online December 10 in the Journal of Urology.
December 10, 2012
Study: Hold the contrast for CT of asymptomatic hematuria
By Edward Susman
In young patients undergoing urograms after a finding of asymptomatic hematuria, it may not be necessary to perform contrast-enhanced CT, as a noncontrast scan may be sufficient, researchers suggested at last week's RSNA meeting.
December 2, 2012
Multiparametric MRI, MR-guided biopsy top TRUS in prostate cancer
By Wayne Forrest
Wednesday, November 28 | 11:40 a.m.-11:50 a.m. | SSK05-08 | Room E353CIn this Wednesday presentation, Dutch researchers will report how repeat 3-tesla multiparametric MRI and MR-guided biopsy outperformed transrectal ultrasound (TRUS) biopsy in upgrading and upstaging patient risk restratification in a prostate cancer study at 12 months of follow-up.
November 14, 2012
Digital tomosynthesis may be alternative to KUB urolithiasis
By Brian Casey
Monday, November 26 | 10:40 a.m.-10:50 a.m. | SSC14-02 | Room S403ADigital tomosynthesis could be a better alternative than conventional kidney, ureter, and bladder (KUB) radiography or unenhanced CT for detecting urinary stones, according to this presentation by Chinese researchers.
November 12, 2012
CADx may improve characterization of central gland lesions
By Erik L. Ridley
Tuesday, November 27 | 3:00 p.m.-3:10 p.m. | SSJ22-01 | Room S403BIn this scientific paper presentation, Dutch researchers will highlight the potential of computer-aided diagnosis (CADx) for differentiating benign and malignant central gland lesions in the prostate.
November 11, 2012
Software offers advanced visualization of prostate MRI
By Erik L. Ridley
Monday, November 26 | 12:45 p.m.-1:15 p.m. | LL-INE-MO8B | Lakeside Learning CenterIn this educational exhibit, German researchers will present an integrated software tool for the automated analysis and advanced visualization of multiparametric MRI of the prostate.
November 11, 2012
MIP reformatting aids in urinary tract stone detection
By Erik L. Ridley
Sunday, November 25 | 11:45 a.m.-11:55 a.m. | SSA10-07 | Room E353BIn this scientific session, researchers will share how coronal maximum intensity projection (MIP) image reformations can improve the detection and measurement of urinary tract stones.
November 11, 2012
FDG-PET/CT plays key role in treatment outcomes of prostate cancer
By Wayne Forrest
Wednesday, November 28 | 11:00 a.m.-11:10 a.m. | SSK13-04 | Room S505ABA preliminary study by researchers at the University of Southern California suggests that FDG-PET/CT provides unique prognostic information on outcomes for men with castrate-sensitive metastatic prostate cancer who are undergoing various forms of hormonal treatment.
November 7, 2012
Previous Page
Page 47 of 93
Next Page